Assessment of Antigen-Specific and Cross-Reactive Antibody Responses to an MF59-Adjuvanted A/H5N1 Prepandemic Influenza Vaccine in Adult and Elderly Subjects

Experimental adaptation of an influenza H5 HA confers respiratory droplet transmission to a reassortant H5 HA/H1N1 virus in ferrets

(2012) Masaki Imai et al.   NATURE

A phase III, randomized, open-label study to assess the tolerability and immunogenicity of an H5N1 influenza vaccine administered to healthy adults with a 1-, 2-, 3-, or 6-week interval between first and second doses

(2011) Jiri Beran et al.   CLINICAL THERAPEUTICS

Long-lasting immunogenicity and safety of a 2009 pandemic influenza A(H1N1) MF59-adjuvanted vaccine when co-administered with a 2009-2010 seasonal influenza vaccine in young patients with Type 1 diabetes mellitus

(2011) G. V. Zuccotti et al.   DIABETIC MEDICINE

MF59 adjuvant: the best insurance against influenza strain diversity

(2011) Derek T O’Hagan et al.   Expert Review of Vaccines

Pre-pandemic and pandemic influenza vaccines

(2011) Steven Rockman et al.   Human vaccines & immunotherapeutics

Passive surveillance of adverse events of an MF59-adjuvanted H1N1v vaccine during the pandemic mass vaccinations

(2011) Angelika Banzhoff et al.   Human vaccines & immunotherapeutics

Combined, Concurrent, and Sequential Administration of Seasonal Influenza and MF59-Adjuvanted A/H5N1 Vaccines: A Phase II Randomized, Controlled Trial of Immunogenicity and Safety in Healthy Adults

(2011) Pio Lopez et al.   JOURNAL OF INFECTIOUS DISEASES

Oil-in-Water Emulsion Adjuvant with Influenza Vaccine in Young Children

(2011) Timo Vesikari et al.   NEW ENGLAND JOURNAL OF MEDICINE

Explorations of clinical trials and pharmacovigilance databases of MF59®-adjuvanted influenza vaccines for associated cases of narcolepsy: A six-month update

(2011) Antonio Crucitti et al.   SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES

Explorations of clinical trials and pharmacovigilance databases of MF59®-adjuvanted influenza vaccines for associated cases of narcolepsy

(2011) Theodore F. Tsai et al.   SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES

MF59 Adjuvant Enhances Diversity and Affinity of Antibody-Mediated Immune Response to Pandemic Influenza Vaccines

(2011) S. Khurana et al.   Science Translational Medicine

Immunogenicity and safety profile of the monovalent A/H1N1 MF59-adjuvanted vaccine in patients affected by cystic fibrosis

(2011) F. Alghisi et al.   THORAX

Antibody responses to natural influenza A/H1N1/09 disease or following immunization with adjuvanted vaccines, in immunocompetent and immunocompromised children

(2011) Sara Meier et al.   VACCINE

Induction of protective antibody response by MF59-adjuvanted 2009 pandemic A/H1N1v influenza vaccine in HIV-1-infected individuals

(2010) Anna Kajaste-Rudnitski et al.   AIDS

A Heterologous MF59-Adjuvanted H5N1 Prepandemic Influenza Booster Vaccine Induces a Robust, Cross-Reactive Immune Response in Adults and the Elderly

(2010) E. Fragapane et al.   Clinical and Vaccine Immunology

MF59™ as a vaccine adjuvant: a review of safety and immunogenicity

(2010) Hana El Sahly   Expert Review of Vaccines

An open-label, randomized clinical trial assessing immunogenicity, safety and tolerability of pandemic influenza A/H1N1 MF59-adjuvanted vaccine administered sequentially or simultaneously with seasonal virosomal-adjuvanted influenza vaccine to paediatric kidney transplant recipients

(2010) S. Esposito et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Immunogenicity and Safety of MF59-Adjuvanted H5N1 Influenza Vaccine From Infancy to Adolescence

(2010) T. Vesikari et al.   PEDIATRICS

Vaccines with MF59 Adjuvant Expand the Antibody Repertoire to Target Protective Sites of Pandemic Avian H5N1 Influenza Virus

(2010) S. Khurana et al.   Science Translational Medicine

Immunogenicity, safety and tolerability of monovalent 2009 pandemic influenza A/H1N1 MF59-adjuvanted vaccine in patients with β-thalassemia major

(2010) Susanna Esposito et al.   VACCINE

Safety of MF59-adjuvanted versus non-adjuvanted influenza vaccines in children and adolescents: An integrated analysis

(2010) Steven Black et al.   VACCINE

MF59®-Adjuvanted H5N1 Vaccine Induces Immunologic Memory and Heterotypic Antibody Responses in Non-Elderly and Elderly Adults

(2009) Angelika Banzhoff et al.   PLoS One

Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine

(2009) G. Galli et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels

(2009) G. Galli et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

MF59®-adjuvanted influenza vaccine (FLUAD®) in children: Safety and immunogenicity following a second year seasonal vaccination

(2009) T. Vesikari et al.   VACCINE

MF59-adjuvanted versus non-adjuvanted influenza vaccines: Integrated analysis from a large safety database

(2009) Michele Pellegrini et al.   VACCINE

Exposure to MF59-adjuvanted influenza vaccines during pregnancy—A retrospective analysis

(2009) Theodore Tsai et al.   VACCINE

Genotypic diversity of H5N1 highly pathogenic avian influenza viruses

(2008) Z.-M. Zhao et al.   JOURNAL OF GENERAL VIROLOGY

Stockpiling prepandemic influenza vaccines: a new cornerstone of pandemic preparedness plans

(2008) Lance C Jennings et al.   LANCET INFECTIOUS DISEASES

Antigenically Distinct MF59-Adjuvanted Vaccine to Boost Immunity to H5N1

(2008) Iain Stephenson et al.   NEW ENGLAND JOURNAL OF MEDICINE